Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Portola Pharmaceuticals Company Profile (NASDAQ:PTLA)

Consensus Ratings for Portola Pharmaceuticals (NASDAQ:PTLA) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $36.65 (41.07% upside)

Analysts' Ratings History for Portola Pharmaceuticals (NASDAQ:PTLA)
Show:
DateFirmActionRatingPrice TargetDetailsShare
8/12/2014ZacksUpgradeNeutral -> Outperform$28.30ViewTweet This Rating  Share This Rating on StockTwits
11/6/2013Cowen and CompanyLower Price TargetOutperform$47.00 -> $45.00ViewTweet This Rating  Share This Rating on StockTwits
8/16/2013Cowen and CompanyBoost Price TargetOutperform$45.37 -> $47.00ViewTweet This Rating  Share This Rating on StockTwits
6/27/2013Sanford C. BernsteinInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
6/20/2013Cowen and CompanyInitiated CoverageOutperform$45.00ViewTweet This Rating  Share This Rating on StockTwits
6/17/2013Credit SuisseReiterated RatingOutperform$30.00 -> $30.00ViewTweet This Rating  Share This Rating on StockTwits
6/17/2013William BlairReiterated RatingOutperformViewTweet This Rating  Share This Rating on StockTwits
6/17/2013Morgan StanleyReiterated RatingOverweightViewTweet This Rating  Share This Rating on StockTwits
(Data available from 9/30/2012 forward)
Discuss Portola Pharmaceuticals